AU4792200A - Parenteral formulation of 5-(2-chloroethyl)-4-methylthiazole edisylate(clomethiazole edisylate) - Google Patents

Parenteral formulation of 5-(2-chloroethyl)-4-methylthiazole edisylate(clomethiazole edisylate)

Info

Publication number
AU4792200A
AU4792200A AU47922/00A AU4792200A AU4792200A AU 4792200 A AU4792200 A AU 4792200A AU 47922/00 A AU47922/00 A AU 47922/00A AU 4792200 A AU4792200 A AU 4792200A AU 4792200 A AU4792200 A AU 4792200A
Authority
AU
Australia
Prior art keywords
edisylate
methylthiazole
chloroethyl
clomethiazole
parenteral formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU47922/00A
Inventor
Ola Camber
Karin Ellstrom
Ingrid Jappinen
Tomas Petersson-Norden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU4792200A publication Critical patent/AU4792200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU47922/00A 1999-05-06 2000-05-04 Parenteral formulation of 5-(2-chloroethyl)-4-methylthiazole edisylate(clomethiazole edisylate) Abandoned AU4792200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9901658A SE9901658D0 (en) 1999-05-06 1999-05-06 New formulation
SE9901658 1999-05-06
PCT/SE2000/000876 WO2000067753A1 (en) 1999-05-06 2000-05-04 Parenteral formulation of 5-(2-chloroethyl)-4-methylthiazole edisylate(clomethiazole edisylate)

Publications (1)

Publication Number Publication Date
AU4792200A true AU4792200A (en) 2000-11-21

Family

ID=20415507

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47922/00A Abandoned AU4792200A (en) 1999-05-06 2000-05-04 Parenteral formulation of 5-(2-chloroethyl)-4-methylthiazole edisylate(clomethiazole edisylate)

Country Status (7)

Country Link
EP (1) EP1178798A1 (en)
JP (1) JP2002544164A (en)
AR (1) AR023873A1 (en)
AU (1) AU4792200A (en)
SE (1) SE9901658D0 (en)
TN (1) TNSN00094A1 (en)
WO (1) WO2000067753A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK733888A (en) * 1988-01-12 1989-07-13 Fujisawa Pharmaceutical Co stabilizer
IL91856A0 (en) * 1988-10-11 1990-06-10 Schiapparelli Salute Spa Pharmaceutical compositions comprising calcitonin for intranasal administration and a spray unit for the administration of the same
SE8900564D0 (en) * 1989-02-17 1989-02-17 Astra Ab NOVEL MEDICINAL USE
SE9002659D0 (en) * 1990-08-15 1990-08-15 Astra Ab NEW PHARMACEUTICAL FORMULATIONS

Also Published As

Publication number Publication date
SE9901658D0 (en) 1999-05-06
TNSN00094A1 (en) 2002-05-30
EP1178798A1 (en) 2002-02-13
AR023873A1 (en) 2002-09-04
WO2000067753A1 (en) 2000-11-16
JP2002544164A (en) 2002-12-24

Similar Documents

Publication Publication Date Title
AU2331000A (en) Hydrophobic starch derivatives
AU5611000A (en) Co-sintering of similar materials
AU2003262023A1 (en) Five-membered heterocyclic compounds
AU2003302763A1 (en) Insecticidal aminothiazole derivatives
EP1274354B8 (en) Device for the articulated connection of two bodies
AU2003255492A1 (en) Heterocyclic derivatives
AU2139500A (en) Plug and play i2c slave
AU5885900A (en) Environmental testing chamber
AU1405100A (en) Open debugging environment
AU2055201A (en) N6 heterocyclic 5' modified adenosine derivatives
AUPP909499A0 (en) Surface modification of rubber objects
AU4395399A (en) Five-membered heteroaryl compounds
AUPQ309399A0 (en) Benzothiazoline derivatives
AU2002224043A1 (en) Legged robot
AU2001248820A1 (en) Thiazole and oxazole derivatives
AU5435400A (en) Low-power sensor
AU9001598A (en) Thiourea derivatives
AU2001286497A1 (en) Water soluble thiazolyl peptide derivatives
AU2001258841A1 (en) Heterocyclic compounds
AU2001293207A1 (en) Nitrogenous heterocyclic compounds
AU3196100A (en) Heterocyclic sulfonamide derivatives
AU2001282865A1 (en) Heterocyclic sulfonamide derivatives
AU2001280470A1 (en) Heterocyclic sulfonamide derivatives
AU6046300A (en) Reduced sensitivity melt-cast explosives
AU2001294665A1 (en) Enzymatically modified hydrophobic starch

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase